Nachrichten und Videos - CRYOPORT INC.

DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics" PR Newswire BONN, Germany and NASHVILLE, Tenn., March 31, 2025 DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics. DHL and Cryoport form strategic...

Cryoport to Host Investor Call to Discuss Recent Strategic Agreement and Transformative Transaction Today, March 31, 2025, at 8:30 a.m. ET PR Newswire NASHVILLE, Tenn., March 31, 2025 NASHVILLE, Tenn. , March 31, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences sector, today announced that the Company will host an investor call today, Monday, March 31, 2025 , at 8:30 a.m. ET , to discuss the...

Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories PR Newswire NASHVILLE, Tenn., March 12, 2025 NASHVILLE, Tenn. , March 12, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of MVE Biological Solutions ' ("MVE") High-Efficiency 800 C, the latest...

Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire NASHVILLE, Tenn., March 4, 2025 FY 2024 revenue of $228.4 million , in-line with company guidance Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting a record total of 701 global clinical trials as of December 31, 2024 NASHVILLE, Tenn. , March 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life...

Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 PR Newswire NASHVILLE, Tenn., Feb. 18, 2025 NASHVILLE, Tenn. , Feb. 18, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2024 on Tuesday, March 4, 2025 after U.S. markets close. In addition...

Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies PR Newswire NASHVILLE, Tenn., Jan. 21, 2025 New High-Volume Shipping System, Improving Patient Accessibility, Will Be Showcased by Cryoport Systems at Phacilitate's Advanced Therapies Week in Dallas NASHVILLE, Tenn. , Jan. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life...

Moffitt Cancer Center and Cryoport Announce Strategic Collaboration PR Newswire TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn. , Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center , a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL , a 775-acre global innovation life sciences campus, and Cryoport, Inc....

Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA") PR Newswire NASHVILLE, Tenn., Jan. 6, 2025 All Three MVE Biological Solutions' Manufacturing Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed NASHVILLE, Tenn. , Jan. 6, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced that MVE Biological...

Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe PR Newswire NASHVILLE, Tenn., Nov. 12, 2024 Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs NASHVILLE, Tenn. , Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced...

Cryoport Reports Third Quarter 2024 Financial Results PR Newswire NASHVILLE, Tenn., Nov. 7, 2024 Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024 Company reaffirmed full year 2024 revenue guidance of $225 to $235 million NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain...

Cryoport to Report Third Quarter 2024 Financial Results on November 7, 2024 PR Newswire NASHVILLE, Tenn., Oct. 29, 2024 NASHVILLE, Tenn. , Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2024 on Thursday, November 7, 2024 after U.S. markets close. In addition to the earnings...

Cryoport and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services PR Newswire NASHVILLE, Tenn. and HOUSTON, Oct. 22, 2024 Partnership Coincides with the Grand Opening of Cryoport's State-Of-The-Art IntegriCell ™ Houston Facility NASHVILLE, Tenn. and HOUSTON , Oct. 22, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and Gulf Coast Regional Blood Center ("GCRBC"),...

TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics PR Newswire NASHVILLE, Tenn. and NEW YORK, Oct. 21, 2024 Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted Solutions for Secure IVF Specimen Management and Transport NASHVILLE , Tenn. and NEW YORK , Oct. 21, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in...

Cryoport Launches its IntegriCell™ Cryopreservation Solution with Opening of New Facility at its Houston Campus PR Newswire NASHVILLE, Tenn., Oct. 7, 2024 The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies NASHVILLE, Tenn. , Oct. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of its IntegriCell™ cryopreservation...

SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices PR Newswire NASHVILLE, Tenn. and RANCHO CORDOVA, Calif., Sept. 25, 2024 NASHVILLE, Tenn. and RANCHO CORDOVA, Calif. , Sept. 25, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and SK pharmteco , a global contract development and manufacturing organization, today announced a strategic collaboration to provide fully...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to participate . We also encourage you to contact Brian...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to participate . We also encourage you to contact Brian...

Cryoport Reports Second Quarter 2024 Financial Results PR Newswire NASHVILLE, Tenn., Aug. 6, 2024 Revenue improved sequentially across all businesses Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total of 684 global clinical trials supported as of June 30, 2024 Cost reduction initiatives anticipated to result in approximately $22 million of annualized cost savings and drive Cryoport towards its goal of profitable growth, as well as a return to...

Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes PR Newswire NASHVILLE, Tenn., Aug. 6, 2024 $200 million repurchase program authorized to repurchase common stock and/or convertible notes Repurchasing approximately $160 million of 0.75% Senior Notes due in 2026 at an 11.5% discount to par value Principal balance reduced to approximately $186.2 million NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX)...

LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to...